Skip to main content

6 Result(s)

within David Tougeron Remove this filter Medicine & Public Health Remove this filter English Remove this filter

and

  1. No Access

    Article

    Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study

    The aim of the IRECAP study was to evaluate the rate of locally advanced pancreas cancer patients (LAPC) who could undergo R0 or R1 surgery after irreversible electroporation (IRE).

    Jean-Pierre Tasu, Guillaume Herpe, Jérôme Damion, Jean-Pierre Richer… in European Radiology (2024)

  2. No Access

    Article

    Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients

    Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal immunoglobulin (Ig)G1 antibody, has been approved for the treatment of metastatic colorectal cancer (mCRC). The influence of target-antigen...

    Sarah Lobet, Gilles Paintaud, Nicolas Azzopardi… in Clinical Pharmacokinetics (2023)

  3. Article

    Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study

    The optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma (OGA) remains challenging.

    Elisabeth S. Bergen, Lorenzo Pilla, Edouard Auclin, Aysegül Ilhan-Mutlu… in Gastric Cancer (2023)

    Download PDF (937 KB) View Article

  4. No Access

    Article

    Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study

    Trastuzumab with fluoropyrimidine and cisplatin is the standard first-line treatment in patients with HER2-positive advanced gastro-esophageal adenocarcinoma. However, there are no safety and efficacy data of ...

    Aziz Zaanan, Juliette Palle, Emilie Soularue, Florence Leroy… in Targeted Oncology (2018)

  5. No Access

    Article

    Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

    It is now well established that metastatic colorectal cancer patients without KRAS mutation (codon 12) benefit from treatment with an epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb). Recently...

    David Tougeron, Ulrich Cortes, Aurélie Ferru… in Cancer Chemotherapy and Pharmacology (2013)

  6. No Access

    Article

    Predicting Factors of Fistula Healing and Clinical Remission After Infliximab-Based Combined Therapy for Perianal Fistulizing Crohn’s Disease

    Perianal fistulizing Crohn’s disease (PFCD) treatment is based on fistula drainage, antibiotics, immunosuppressant (IS) drugs, and infliximab. Our aim was to study the effectiveness of combination therapy on P...

    David Tougeron, Guillaume Savoye, Céline Savoye-Collet… in Digestive Diseases and Sciences (2009)